Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by GoBBson May 06, 2020 12:25pm
109 Views
Post# 30993479

Eventually without material progress

Eventually without material progressthey will once again run out of money ...The issue they will have is next time they will not be able to raise one penny from retail because of their track record of zero progress, underhand takeover and massive greed in salaries and renumeration. This would set the stage for this to go under or for sale. If Charm is right and they are missing pieces of the Ryplazim manufacturing puzzle then Ryplazim is done ..that leaves 4050 with no placebo trials completed. Looking pretty ugly.
<< Previous
Bullboard Posts
Next >>